Published in J Interv Card Electrophysiol on July 22, 2017
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost (2005) 2.16
Beyond unfractionated heparin and warfarin: current and future advances. Circulation (2007) 1.52
A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol (2012) 1.08
Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol (2014) 1.01
Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb Res (2015) 0.99
Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb Haemost (2010) 0.97
Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ Res (2014) 0.97
Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol (2014) 0.97
Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93
Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. J Thromb Haemost (2013) 0.88
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. J Interv Card Electrophysiol (2014) 0.86
NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart (2016) 0.84
Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level? Ann Pharmacother (2015) 0.83
Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis. Can J Cardiol (2015) 0.83
A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. Clin Drug Investig (2013) 0.81
Advances in atrial fibrillation ablation. J Invasive Cardiol (2009) 0.80
Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis (2017) 0.75